Gravitational search algorithm: A new feature selection method for QSAR study of anticancer potency of imidazo[4,5-b]pyridine derivatives

Chemometrics and Intelligent Laboratory Systems

Volumn 122, Issue , 2013, Pages 1-11

  Mohseni Bababdani, Behnam ^a   Mousavi, Mehdi ^a  

^a SHAHID BAHONAR UNIVERSITY OF KERMAN   (Iran)

Author keywords

Anti cancer potency; Aurora A kinase; Feature selection; Gravitational search algorithm; Imidazo 4,5 b pyridine; QSAR study

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDAZO[4,5 B]PYRIDINE DERIVATIVE;

ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; BAYESIAN LEARNING; BIOLOGICAL ACTIVITY; DRUG ANALYSIS; GENETIC ALGORITHM; GRAVITATIONAL SEARCH ALGORITHM; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOMIZATION;

EID: 84872385817     PISSN: 01697439     EISSN: 18733239     Source Type: Journal    
DOI: 10.1016/j.chemolab.2012.12.002     Document Type: Article

References (67)

1. Bolanos-Garcia V.M. Aurora kinases. The International Journal of Biochemistry & Cell Biology 2005, 37:1572-1577.
2. World Health Organization Media centre (accessed February 2012). http://www.who.int/mediacentre/factsheets/fs297/en.
3. Siegel R., Ward E., Brawley O., Naishadham D., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians 2011, 61:212-236.
4. Chan F., Sun C., Perumal M., Nguyen Q.D., Bavetsias V., McDonald E., Martins V., Wilsher N.E., Raynaud F.I., Valenti M., Eccles S., te Poele R., Workman P., Aboagye E.O., Linardopoulos S. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics 2007, 6:3147-3157.
5. Paris J., Philippe M. Poly(A) metabolism and polysomal recruitment of maternal mRNAs during early Xenopus development. Developmental Biology 1990, 140:221-224.
6. Carmena M., Earnshaw W.C. The cellular geography of aurora kinases. Nature Reviews Molecular Cell Biology 2003, 4:842-854.
7. Chiang C.C., Lin Y.H., Lin S.F., Lai C.L., Liu C., Wei W.Y., Yang S.C., Wang R.W., Teng L.W., Chuang S.H., Chang J.M., Yuan T.T., Lee Y.S., Chen P., Chi W.K., Yang J.Y., Huang H.J., Liao C.B., Huang J.J. Discovery of pyrrole-indoline-2-ones as aurora kinase inhibitors with a different inhibition profile. Journal of Medicinal Chemistry 2010, 53:5929-5941.
8. Giet R., Petretti C., Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link?. Trends in Cell Biology 2005, 15:241-250.
9. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M., Hoar K.M., Huck J.J., Le Roy P.J., Ray E.T., Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4106-4111.
10. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M.C., Miller K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Medicine 2004, 10:262-267.
11. Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., Vianello P. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. Journal of Medicinal Chemistry 2006, 49:7247-7251.
12. Carpinelli P., Ceruti R., Giorgini M.L., Cappella P., Gianellini L., Croci V., Degrassi A., Texido G., Rocchetti M., Vianello P., Rusconi L., Storici P., Zugnoni P., Arrigoni C., Soncini C., Alli C., Patton V., Marsiglio A., Ballinari D., Pesenti E., Fancelli D., Moll J. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Molecular Cancer Therapeutics 2007, 6:3158-3168.
13. González-Díaz H., Bonet I., Terán C., De Clercq E., Bello R., García M.M., Santana L., Uriarte E. ANN-QSAR model for selection of anticancer leads from structurally heterogeneous series of compounds. European Journal of Medicinal Chemistry 2007, 42:580-585.
14. Grover M., Singh B., Bakshi M., Singh S. Quantitative structure-property relationships in pharmaceutical research-Part 1. Pharmaceutical Science & Technology Today 2000, 3:28-35.
15. Testa B. Structure-activity-relationships-challenges and context. Pharmaceutical News 2000, 7:13-22.
16. Kaiser K.L.E. Quantitative structure-activity relationships in chemistry. Can. Chemical News 1999, 51:23-24.
17. Fujita T. Recent success stories leading to commercialisable bioactive compounds with the aid of traditional QSAR procedures. Quantitative Structure-Activity Relationships 1997, 16:107-112.
18. Prado-Prado F.J., García I., García-Mera X, González-Díaz H. Entropy multi-target QSAR model for prediction of antiviral drug complex networks. Chemometrics and Intelligent Laboratory Systems 2011, 107:227-233.
19. Moorthy N.S.H.N., Ramos M.J., Fernandes P.A. Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chemometrics and Intelligent Laboratory Systems 2011, 109:101-112.
20. Morales A.H., Duchowicz P.R., Pérez M.Á.C., Castro E.A., Cordeiro M.N.D.S., González M.P. Application of the replacement method as a novel variable selection strategy in QSAR. 1. Carcinogenic potential. Chemometrics and Intelligent Laboratory Systems 2006, 81:180-187.
21. http://www.edusoft-lc.com/molconn.
22. Katritsky A., Karelso M., Lobanov V.S., Dennington R., Keith T. CODESSA, Software version 2.7.2 2004.
23. Todeschini R., Consonni V., Mauri A., Pavan M. DRAGON, Software version 3.0 2003.
24. Zhou X.B., Han W.J., Chen J., Lu X.Q. QSAR study on the interactions between antibiotic compounds and DNA by a hybrid genetic-based support vector machine. Monatshefte fur Chemie 2011, 142:949-959.
25. Zupan J., Zuperl P. Linear vs. Non-linear Modelling. Case study: modelling of binding affinity of inhibitors to Trypsin. Acta Chimica Slovenica 2011, 58:485-491.
26. Zhou X., Li Z., Dai Z., Zou X. QSAR modeling of peptide biological activity by coupling support vector machine with particle swarm optimization algorithm and genetic algorithm. Journal of Molecular Graphics and Modelling 2010, 29:188-196.
27. Shamsipur M., Zare-Shahabadi V., Hemmateenejad B., Akhond M. An efficient variable selection method based on the use of external memory in ant colony optimization. Application to QSAR/QSPR studies. Analytica Chimica Acta 2009, 646:39-46.
28. 7) receptor inhibitors using modified ant colony algorithm and adaptive neuro-fuzzy interference system (ANFIS). European Journal of Medicinal Chemistry 2009, 44:1463-1470.
29. Wen J.-H., Zhong K.-J., Tang L.-J., Jiang J.-H., Wu H.-L., Shen G.-L., Yu R.-Q. Adaptive variable-weighted support vector machine as optimized by particle swarm optimization algorithm with application of QSAR studies. Talanta 2011, 84:13-18.
30. Prakasvudhisarn C., Lawtrakul L. Feature Set Selection in QSAR of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) Analogues by Using Swarm Intelligence. Monatshefte fur Chemie 2008, 139:197-211.
31. Holland J.H. Adaptation in Natural and Artificial Systems 1975, The University of Michigan Press, Ann Arbor, Michigan.
32. Dorigo M., Maniezzo V., Colorni A. The ant system: optimization by a colony of cooperating agents. IEEE Transactions on Systems, Man, and Cybernetics Part B: Cybernetics 1996, 26:29-41.
33. Kennedy J., Eberhart R.C. Particle swarm optimization. Proceedings of IEEE international conference on neural networks, the University of Western Australia Perth, Western Australia 1995, vol. 4:1942-1948.
34. Walters W.P., Goldman B.B. Feature selection in quantitative structure-activity relationships. Current Opinion in Drug Discovery & Development 2005, 8:329-333.
35. Goodarzi M., Dejaegher B., Vander Heyden Y. Feature selection methods in QSAR studies. Journal of AOAC International 2012, 95:636-651.
36. Rashedi E., Nezamabadi-pour H., Saryazdi S. GSA: a gravitational search algorithm. Informational Sciences 2009, 179:2232-2248.
37. Rashedi E., Nezamabadi-pour H., Saryazdi S. BGSA: binary gravitational search algorithm. Natural Computing 2010, 9:727-745.
38. Jain A., Zongker D. Feature selection: evaluation, application, and small sample performance. IEEE Transactions on Pattern Analysis and Machine Intelligence 1997, 19:153-158.
39. Guyon I., Elisseeff A. An introduction to variable and feature selection. Journal of Machine Learning Research 2003, 3:1157-1182.
40. Kirkpatrick S., Gelatto C.D., Vecchi M.P. Optimization by simulated annealing. Science 1983, 220:671-680.
41. Farmer J.D., Packard N.H., Perelson A.S. The immune system, adaptation and machine learning. Physica D 1986, 22:187-204.
42. Karaboga D. An Idea Based On Honey Bee Swarm for Numerical Optimization. Technical Report-TR06 2005, Erciyes University, Engineering Faculty, Computer Engineering Department.
43. a modeling and prediction of a series of pH indicators through genetic algorithm-least square support vector regression. Chemometrics and Intelligent Laboratory Systems 2010, 101:102-109.
44. Goodarzi M., Freitas M.P., Jensen R. Ant colony optimization as a feature selection method in the QSAR modeling of anti-HIV-1 activities of 3-(3,5-dimethylbenzyl)uracil derivatives using MLR, PLS and SVM regressions. Chemometrics and Intelligent Laboratory Systems 2009, 98:123-129.
45. Ruan Z., Wang H., Ren Y., Chen Y., Han J., Pang X., Liang H., Wu Y. Pseudo receptor probes: a novel pseudo receptor-based QSAR method and application into studies on a new kind of selective vascular endothelial growth factor-2 receptor inhibitors. Chemometrics and Intelligent Laboratory Systems 2008, 92:157-168.
46. Tarasewich P., McMullen P.R. Swarm intelligence: power in numbers. Communications of the ACM 2002, 45:62-67.
47. Hamming R.W. Error detecting and error correcting codes. The Bell System Technical Journal 1950, 29:147-160.
48. Haykin S. NEURAL NETWORKS: A Comprehensive Foundation 1999, 60-67. Pearson Education, Inc., Ontario, Canada. second ed.
49. Kecman V. Learning and Soft Computing: Support Vector Machines, Neural Networks, and Fuzzy Logic Models 2001, 1-67. The MIT Press, Massachusetts.
50. Fausett L. Fundamentals of Neural Networks: Architectures, Algorithms and Applications 1994, 289-329. Prentice Hall, Englewood Cliffs.
51. The Handbook of Brain Theory and Neural Networks 2003, 470-475. The MIT Press, Massachusetts, (part 3). M.A. Arbib (Ed.).
52. Burden F.R., Winkler D.A. Robust QSAR models using Bayesian regularized neural networks. Journal of Medicinal Chemistry 1999, 42:3183-3187.
53. Jalali-Heravi M., Mani-Varnosfaderani A. QSAR modeling of 1-(3,3-diphenylpropyl)-piperidinyl amides as CCR5 modulators using multivariate adaptive regression spline and Bayesian regularized genetic neural networks. QSAR and Combinatorial Science 2009, 28:946-958.
54. Mackay D.J.C. Bayesian interpolation. Neural Computation 1992, 4:415-447.
55. Mackay D.J.C. A practical Bayesian framework for backpropagation networks. Neural Computation 1992, 4:448-472.
56. Mackay D.J.C. Probable networks and plausible predictions-a review of practical Bayesian methods for supervised neural networks. Computation in Neural Systems 1995, 6:469-505.
57. Buntine W.L., Weigend A.S. Bayesian back-propagation. Complex Systems 1991, 5:603-643.
58. Caballero J., Candidor-Camba A., Fernandez M. Modeling of the inhibition constant (Ki) of some cruzain ketone-based inhibitors using 2D spatial autocorrelation vectors and data-diverse ensembles of Bayesian-regularized genetic neural networks. QSAR and Combinatorial Science 2007, 26:27-40.
59. Bavetsias V., Sun C., Bouloc N., Reynisson J., Workman P., Linardopoulos S., McDonald E. Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. Bioorganic & Medicinal Chemistry Letters 2007, 17:6567-6571.
60. Bavetsias V., Large J.M., Sun C., Bouloc N., Kosmopoulou M., Matteucci M., Wilsher N.E., Martins V., Reynisson J., Atrash B., Faisal A., Urban F., Valenti M., Brandon A.H., Box G., Raynaud F.I., Workman P., Eccles S.A., Bayliss R., Blagg J., Linardopoulos S., McDonald E. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. Journal of Medicinal Chemistry 2010, 53:5213-5228.
61. Tropsha A., Gramatica P., Gomber V.K. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSAR models. QSAR and Combinatorial Science 2003, 22:69-77.
62. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Montgomery J.A., Vreven T., Kudin K.N., Burant J.C., Millam J.M., Iyengar S.S., Tomasi J., Barone V., Mennucci B., Cossi M., Scalmani G., Rega N., Petersson G.A., Nakatsuji H., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Klene M., Li X., Knox J.E., Hratchian H.P., Cross J.B., Adamo C., Jaramillo J., Gomperts R., Stratmann R.E., Yazyev O., Austin A.J., Cammi R., Pomelli C., Ochterski J.W., Ayala P.Y., Morokuma K., Voth G.A., Salvador P., Dannenberg J.J., Zakrzewski V.G., Dapprich S., Daniels A.D., Strain M.C., Farkas O., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Ortiz J.V., Cui Q., Baboul A.G., Clifford S., Cioslowski J., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Gonzalez C., Pople J.A. Gaussian 03, Revision B.03 2003, Gaussian, Inc., Pittsburgh PA.
63. Jalali-Heravi M., Asadollahi-Baboli M., Shahbazikhah P. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberge-Marquardt algorithm. European Journal of Medicinal Chemistry 2008, 43:548-556.
64. Saiz-Urra L., Gonzalez M.P., Teijeira M. QSAR studies about cytotoxicity of benzophenazines with dual inhibition toward both topoisomerases I and II: 3D-MoRSE descriptors and statistical considerations about variable selection. Bioorganic & Medicinal Chemistry 2006, 14:7347-7358.
65. Cheng Z., Zhang Y., Fu W. QSAR study of carboxylic acid derivatives as HIV-1 Integrase inhibitors. European Journal of Medicinal Chemistry 2010, 45:3970-3980.
66. Gonzalez M.P., Suarez P.L., Falla Y., Gomez G. Quantitative structure-activity relationship studies of vitamin D receptor affinity for analogues of 1a,25-dihydroxyvitamin D3. 1: WHIM descriptors. Bioorganic & Medicinal Chemistry Letters 2005, 15:5165-5169.
67. Rastija V., Medic-Saric M. QSAR study of antioxidant activity of wine polyphenols. European Journal of Medicinal Chemistry 2009, 44:400-408.